Open access
Jul 2026
Real‐world implementation of lecanemab in Alzheimer's disease: A Japanese cohort
Real‐world evidence for lecanemab remains limited, particularly among Asian populations. We evaluated the feasibility, safety, biomarker profiles, and short‐term clinical outcomes of lecanemab in practice in Japan.
S. Shimohama, S. Bun, Ryo Shikimoto et al.
· Alzheimer's & Dementia · 1 citation